Christopher M Fife

Translational Scientist | CRUK National Biomarker Centre | University of Manchester, UK | Immunooncology | NSCLC/SCLC/CRC | 🇦🇺🇬🇧🇦🇹

[Charles Swanton @CharlesSwanton]

We managed to get one last paper https://t.co/AwA1rYKefr over the line before the new year🥂! We are pleased to share the first Nature Cell Biology paper from our lab functionally validating the role of a frequently occurring lung cancer driver, FAT1 in cancer evolution. 🧵1/13

[Toni Choueiri, MD @DrChoueiri]

Paper 6:

#ChalabiPlot (aka @MyriamChalabi) strikes again! Results from the NICHE-2 trial initially presented @myESMO 2022 now @NEJM:

near 100% pathologic response with neoadjuvant nivo/ipi in dMMR colon cancer

https://t.co/NQdlzvPNzs

[Journal for ImmunoTherapy of Cancer @jitcancer]

Read the full report here: https://t.co/8wuM6AQAwL 6/6

[Journal for ImmunoTherapy of Cancer @jitcancer]

Here’s a closer look at #JITC article “Natural killer cells are required for the recruitment of CD8+ T cells & the efficacy of immune checkpoint blockade in melanoma brain metastases” by @C_M_Fife @Lorgerlab @SalmondLeeds @VHIT_Mckimmie @zarnazhadi at @LIMRLeeds @LIDA_UK @UniversityLeeds. 1/6

[Clive McKimmie (VHIT) 🦟🦠🐁 @VHIT_Mckimmie]

Cool paper out by the @Lorgerlab showing how NK cells are crucial for efficient CD8 recruitment that enables efficacious immunotherapy to brain melanoma mets. Huge amount of work by the key authors, and was pleasure to contribute our small part.
https://t.co/uFDllcU3RF

[MANIFEST IO @MANIFEST_CIRRP]

📺 As seen on @BBCBreakfast this morning.

Hear first-hand from Prof Turajlic @TurajlicLab, project lead of MANIFEST, and Prof Dive @cruk_nbc discuss our vision and ambitions for the programme.

🔗https://t.co/W9DrW3o9hU (from 07:17 | 6th Oct 2024)

[Nicholas McGranahan @NickyMcGranahan]

Together with @CharlesSwanton, delighted to share that our new tool, MHC Hammer - which can detect different types of HLA disruption - mutation, loss, RNA repression and alt. splicing - is now out in #NatureGenetics and available to use…https://t.co/pNGyLKsmmG...
🧵below

[CRUK Manchester Institute @CRUK_MI]

It's been a busy day for @CRUK_MI and @cruk_nbc #PhD students at the EACR conference @EACRnews!

Victoria's work "COX-2-associated inflammation as a relapse #biomarker for early-stage lung cancer" is presented at Poster P033 #EACR2024

[Hans Clevers @HansClevers]

🔍Understanding genetic mutations & signaling pathways is key to advancing personalized therapies for #ColorectalCancer. This study is a crucial step toward more effective treatments. Learn more: https://t.co/CnrV5oYRyj #CancerResearch #FBXW7 #EGFRSignaling

[Cancer Cell @Cancer_Cell]

Online Now: Phenotypic signatures of circulating neoantigen-reactive CD8+ T cells in patients with metastatic cancers https://t.co/SBJlb6aCT1

[Klebanoff_Lab @KlebanoffLab]

🚨🧬💉Everything you wanted to know about TCR therapies* (*but were afraid to ask). Check out our new review in @NatRevDrugDisc 👇. A wonderful collaboration between @KlebanoffLab, @ND_BakerLab, @QuezadaLab, and @ToniRibas12. @MSKCancerCenter @parkerici https://t.co/HfBSUi7e6D

[Charles Swanton @CharlesSwanton]

Wonderful summary of TRACERx latest data by Prof Mitsudomi reviewing ⁦@crispinhiley⁩ ⁦@SonyaHessey⁩ and Wing Liu work - Clonal TMB , metastasis growth rates and Immune evasion mechanisms - thanks ⁦@TheCrick⁩ ⁦@uclcancer⁩ ⁦@CRUK_MI⁩ @CRUKresearch⁩

[Stephen V Liu, MD @StephenVLiu]

#ESMO23 Dr. @dplanchard presents an important update on FLAURA2. Phase III study of 1L osimertinib alone or with platinum + pemetrexed. Dr. Pasi Janne had presented the efficacy results at #WCLC23 that showed PFS improvement (HR 0.62 - mPFS 19.9m vs 29.4m by BICR). #LCSM

[James Black @jrm_black]

Sharing new data from #TRACERx this morning.

🟡 Pre-op #ctDNA stratifying 171 patients with untreated early stage #NSCLC studied using ultra-sensitive assay @PersonalisInc

🟡 Adenos had 100% 5yr OS if ctDNA -ve

🟡 ctDNA +ve <80 PPM poor OS/RFS vs ctDNA -ve

#LCSM #ESMO23

[Graham Heimberg @gheimberg]

Ever analyze a scRNAseq dataset and wonder if a specific cell state has been seen before? And if so, where in the human body? Under what conditions? Well, now you can use our lightning fast SCimilarity search and foundational model for that! ⚡️🔎🧬 https://t.co/t8L1xFOffd (1/11)

[Stephen V Liu, MD @StephenVLiu]

Dr. Martin Wermke presents data on BI 764532 - a new bispecific T cell engaged towards DLL3 and CD3 in #SCLC. Initially q3w then used a weekly step up strategy. 57 SCLC, 41 extrapulmonary small cell, 9 LCNEC. #ASCO23

[DS(Dongsung) Kim @dskim22]

https://t.co/shLMqgPubZ
I am excited to share my recent publication in Nature! This is my postdoctoral work and has been published as of today. The story is about a new pan-KRAS inhibitor that can target multiple mutations in KRAS, which is a frequently mutated protein in cancer.

[Norbert Kraut @norbertkraut1]

Thrilled to share that our paper on Pan-KRAS inhibitors is now live @Nature. Inhibitors prevent activation of WT and a broad range of #KRAS mutants, while sparing HRAS+NRAS. Congrats to collaborators @boehringer and @mskcc. #PrecisionOncology @OncoAlert
https://t.co/40IZvE0O5E

[Christopher M Fife @C_M_Fife]

@D_B_McConnell Congrats @D_B_McConnell @norbertkraut1 @BoettcherJark and team BI. A big leap forward for #KRASKickers

[Darryl B McConnell @D_B_McConnell]

Why inhibit only one KRAS mutant when you can inhibit multiple KRAS alterations at the same time.

Our pan-KRAS inhibitor paper is out.

https://t.co/Fya75XuSv1